key: cord-1044100-4rwid2se
authors: Errico, John M.; Zhao, Haiyan; Chen, Rita E.; Liu, Zhuoming; Case, James Brett; Ma, Meisheng; Schmitz, Aaron J.; Rau, Michael J.; Fitzpatrick, James A.J.; Shi, Pei-Yong; Diamond, Michael S.; Whelan, Sean P.J.; Ellebedy, Ali H.; Fremont, Daved H.
title: Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
date: 2021-10-08
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109881
sha: 9308aa363b9c28a67148835b041acc194acbf435
doc_id: 1044100
cord_uid: 4rwid2se

The SARS-CoV-2 pandemic has necessitated the rapid development of antibody-based therapies and vaccines as countermeasures. Here, we use cryo-EM to characterize two protective anti-SARS-CoV-2 murine monoclonal antibodies (mAbs) in complex with the spike protein, revealing similarities between epitopes targeted by human and murine B-cells. The more neutralizing mAb, 2B04, binds the receptor-binding motif (RBM) of the receptor binding domain (RBD) and competes with ACE2. In contrast, 2H04 binds adjacent to the RBM and does not compete for ACE2 binding. Naturally occurring sequence variants of SARS-CoV-2, and corresponding neutralization escape variants selected in vitro map to our structurally defined epitopes, suggesting that SARS-CoV-2 might evade therapeutic antibodies with a limited set of mutations, underscoring the importance of combination mAb therapeutics. Finally, we show that 2B04 neutralizes SARS-CoV-2 infection by preventing ACE2 engagement, whereas 2H04 reduces host cell attachment without directly disrupting ACE2-RBM interactions, providing distinct inhibitory mechanisms employed by RBD-specific mAbs.

, is a positive-sense RNA virus in the Betacoronavirus genus. It is closely related to other highly pathogenic coronaviruses, most notably Severe Acute Respiratory Syndrome effect on ACE2 binding, suggesting that 2H04 might not compete with ACE2 for binding to the RBD. 152 153 2B04 and 2H04 share epitopes with human antibodies 154 Several groups have identified epitopes on the RBD of the SARS-CoV-2 spike protein (Barnes et al., 155 2020b (Barnes et al., 155 , 2020a Cao et al., 2020; Hansen et al., 2020; Hurlburt et al., 2020; Ju et al., 2020; Liu et al., 156 2020a Liu et al., 156 , 2020b Lv et al., 2020; Pinto et al., 2020; Shi et al., 2020; Wu et al., 2020a Wu et al., , 2020b directly block ACE2 binding, each group also has unique interactions with the RBM (Figure 3C ). All 170 five groups have footprints that overlap extensively with contact residues between the RBD and 171 ACE2, consistent with their ability to neutralize SARS-CoV-2 by blocking interaction with ACE2 172 ( Figure 3C ).

For 2H04, two antibodies were identified that overlapped its footprint: the SARS-CoV cross-174 reactive mAb S309, and SARS-CoV-2 specific C135 ( Figure 3B , magenta group) (Barnes et al., shows that S309 makes more extensive contacts with the N-terminus of the RBD as well as the β1 179 strand (residues 353 to 358), whereas 2H04 makes unique contacts with N448, N450, and P499 180 ( Figure 3C) . In contrast to both 2H04 and S309, C135 displays fewer contacts overall to the RBD, but 181 makes a number of unique contacts, W436, N437, and S438 (Barnes et al., 2020b) . 12 out of 19, and 182 9 out of 20 contact residues are strictly conserved between SARS-CoV-2 and SARS-CoV S for 2H04 183 and 2B04, respectively, suggesting these mAbs might cross-react to SARS-CoV. Quantitative binding 184 analysis by BLI showed weak binding to SARS-CoV by 2H04, with a K D of 1417 nM and half-life of 185 0.43 min; 2B04 did not bind to SARS-CoV RBD at the tested concentrations ( Figure S5C and S5D) 186 (Alsoussi et al., 2020a) .

Proximal to the 2H04/S309 epitope are four additional groups of antibodies. Immediately 188 adjacent and partially overlapping with the 2H04/S309 epitope is REGN-10987 ( Figure 3B , blue 189 group) (Hansen et al., 2020) . Further rotated away from 2H04 and REGN-10987 are three groups 190 targeting similar yet distinct epitopes, bound by H014 ( Figure 3B , light blue group) (Lv et al., 2020) , 191 COVA1-16 ( Figure 3B , dark green group) , and CR3022 or EY6A ( Figure 3B , light 192 green group) Zhou et al., 2020a) , respectively.

Overall, the RBD appears to be highly immunogenic with a multitude of epitopes that cluster 194 roughly into three distinct groups. Antibodies targeting the RBM ridge and loop are differentiated by 195 their orientation of binding on the ridge but share a common mechanism of action and tend to display 

Escape from antibody-mediated neutralization by mutation of key binding residues is a feature of RNA 203 viruses that hinders therapeutic development. A wide variety of amino acid substitutions in the spike 204 J o u r n a l P r e -p r o o f protein of SARS-CoV-2 have been observed in human infections, suggesting that SARS-CoV-2 might be able to escape antibody-mediated neutralization. Escape mutations generated using a SARS-CoV- . Interrogation of human-derived SARS-CoV-2 sequences in the GISAID database via 209 COV-GLUE revealed naturally occurring variants with substitutions at identical residues (Figure 4B, 210 Table 1 ) (Shu and McCauley, 2017; Singer et al., 2020) . T345, R346, L441, and K444 lie outside the 211 binding site for ACE2 ( Figure 4C ) and are all contained within the epitope for 2H04 (Figure 4D 

219 Several novel strains of SARS-CoV-2 bearing mutations in the RBD have emerged since late 2020, 220 some of which contain substitutions at E484, suggesting that these strains may not be as sensitive to 221 neutralization by 2B04 and 2H04 ( Figure 5B) 

Based on our structural analysis and previous reports, 2B04 potently neutralizes SARS-CoV-2 by 235 blocking ACE2 binding, while 2H04 neutralizes less potently without blocking ACE2 ( Figure 6A and 236 6B) . To begin to understand why 2H04 is less efficient at neutralizing SARS2-CoV-2 compared to 237 2B04, we measured the binding affinities of these two mAbs to recombinant RBD expressed in E. coli 

To investigate the neutralization mechanisms of 2B04 and 2H04, we performed a BLI-based 247 competition binding assay. When 2B04 was immobilized, the binding of ACE2 to captured RBD was 248 abrogated (Figure 6E ), consistent with our structural predictions ( Figure 6A ). In contrast, 2H04 failed 249 to block ACE2 binding, suggesting it might neutralize SARS-CoV-2 in a non-ACE2-competitive 250 manner, also in agreement with our structural predictions ( Figure 6B) . Additionally, 2B04 and 2H04 251 were able to bind RBD simultaneously, supporting our structural observations that 2B04 and 2H04 252 recognize spatially distinct epitopes (Figure 2E , 6A, and 6B).

We next performed pre-and post-attachment neutralization assays using a GFP-expressing 254 replication-competent VSV-SARS-CoV-2 chimeric virus on Vero E6-TMPRSS2 cells (Case et al., 255 2020). 2B04 and 2H04 were incubated with VSV-SARS-CoV-2 before or after virus adsorption to the 256 cell surface, and infection was monitored 8 hours post-infection by flow cytometry. 2B04 efficiently 257 J o u r n a l P r e -p r o o f inhibited VSV-SARS-CoV-2 infection when mixed with the virus before or after cell attachment infection more efficiently when added before virus attachment to cells. Thus, 2H04 likely affects viral To further explore how 2H04 neutralizes SARS-CoV-2, we used quantitative real-time PCR

(qRT-PCR) to perform a cellular attachment inhibition assay with authentic SARS-CoV-2 on Vero E6-263 TMPRSS2 cells. As expected, 2B04 prevented SARS-CoV-2 attachment compared to the control 264 mAb (hE16), which agrees with our ACE2 competition binding results and indicates that 2B04 

Recent studies have suggested that some neutralizing antibodies inhibit SARS-CoV-2 270 infection more potently than their monovalent Fab derivatives (Barnes et al., 2020b; Hansen et al., 271 2020; Liu et al., 2020a) . To understand if 2B04 or 2H04 also utilize avidity to neutralize SARS-CoV-2,

we tested their potency in both bivalent and monovalent formats against chimeric VSV-SARS-CoV-2.

Both 2B04 and 2H04 Fabs still showed inhibitory activity against VSV-SARS-CoV-2, with a ~50-and 274 ~560-fold decrease in neutralization potency compared to intact 2B04 and 2H04 IgGs, respectively 275 ( Figure S6 ). These data suggest that bivalent 2B04 and 2H04 IgG inhibit virus infection more 276 effectively than their Fab derivatives.

We have shown that two potently neutralizing mouse antibodies target distinct epitopes on the SARS-

CoV-2 RBD, with one engaging the RBM and another binding nearby. Notably, both 2B04 and 2H04 281 target epitopes shared by human mAbs (i.e., 2-4 for 2B04 and S309 for 2H04). This suggests that 282 these epitopes are immunogenic in both humans and mice, and highlights the possibility of raising 283 therapeutic antibodies in animals.

J o u r n a l P r e -p r o o f It was noted recently that certain antibodies targeting the RBM epitope, such as CC12.1 and 285 B38, preferentially utilize the human IgHV3-53 heavy chain gene and display relatively little somatic 286 hypermutation (Yuan et al., 2020b) . CC12.1 showed only 4 somatic mutations, whereas CC12.3 287 showed 3 substitutions and a deletion compared to its germline precursor (Yuan et al., 2020b) .

IgBLAST analysis of 2B04 shows a similarly low number of somatic mutations, with only 3 amino acid 289 substitutions in the heavy chain and 2 in the light chain ( Figure S7A and B) . In contrast, 2H04 290 showed 6 heavy chain mutations and 5 light chain mutations (Figure S7C and D) . Interestingly, 291 despite bearing half as many somatic mutations as 2H04, 2B04 displays approximately 40-fold higher 292 binding affinity for SARS-CoV-2 RBD (Figure 6C and D) . Also notable is the conservation of paratope 293 contact residues in 2B04. Only 2 of 15 contact residues in the heavy chain were mutated, with one of 294 the two bearing a functionally conservative S31N mutation. 7 of these contact residues also were 295 identical in the human IgHV3-53 gene, with a further 6 bearing conservative substitutions. Only two 296 residues in 2B04 were completely non-conserved compared to human IgHV3-53, I30 and N58 (S30 297 and Y58 in IgHV3-53). Like IgHV3-53-derived antibodies in humans, the epitope targeted by 2B04 298 also appears to be relatively immunodominant in mice, as clonally and functionally similar antibodies 299 have been identified (Alsoussi et al., 2020a; Hassan et al., 2020) .

One notable feature of 2B04 is its ability to bind RBD subunits in both the 'up' and 'down' 301 conformation ( Figure 1A , 1B, and 6H). mAb 2-4 was only reported to bind 'down' RBDs, whereas 302 antibodies targeting the opposite flank of the RBM, such as CC12.1, only bind to RBD in the 'up' 303 conformation (Barnes et al., 2020a; Liu et al., 2020b; Wu et al., 2020a; Yuan et al., 2020b) . Notably, 304 the antibody BD23 was observed to bind only one 'down' RBD per trimer ,

suggesting that binding orientation on the RBM ridge modulates antibody binding stoichiometry to 306 SARS-CoV-2 spike trimers. Because antibodies in these groups tend to display low ng/mL IC 50 307 values, more studies are needed to determine if differential binding stoichiometry has functional 308 consequence. It is worth noting, however, that 2B04 appears to be the most potently neutralizing 309 antibody covered in our analysis (IC 50 of 1.47ng/mL against authentic virus). Additionally, a few other 310 RBM antibodies which have been shown to bind both 'up' and 'down' RBDs, such as COVA2-15 and 311 J o u r n a l P r e -p r o o f C144, display similarly potent neutralization (IC 50 of 9ng/mL against authentic virus for COVA2-15, Chi et al., 2020) . S309 and 47D11 are mAbs that bind RBD but cannot block 316 spike binding to ACE2 (Pinto et al., 2020; Wang et al., 2020) . We have shown that although 2H04 317 does not block ACE2 binding to the isolated RBD, it still impedes virus attachment as efficiently as the 318 ACE2-blocking mAb 2B04, and unlike 2B04, loses much of its potency against virions already 319 attached to host cells. These data indicate there may be alternative attachment receptor(s) in addition 320 to ACE2 that 2H04 is blocking. Indeed, heparan sulfates and C-type lectins (DC-SIGN or L-SIGN) SARS-CoV-2 by inhibiting viral binding to target cell surfaces via unknown receptors or attachment 324 factors. Importantly, these experiments do not exclude the possibility that 2H04 can block the trimeric 325 spike binding ACE2 by selecting a particular spike conformation or otherwise sterically preventing 326 dimeric ACE2 engagement (Barnes et al., 2020b; Huo et al., 2020; Liu et al., 2020a) . Further studies 327 will be required to delineate which of these possibilities plays a dominant role in neutralization.

An antibody identified in a SARS-CoV patient from 2003, mAb S309, was shown to cross-329 neutralize SARS-CoV-2 (Pinto et al., 2020) . Both S309 and 2H04 target an overlapping RBM-adjacent 330 epitope with a relatively high degree of conservation of contact residues between SARS-CoV and 331 SARS-CoV-2. Both antibodies, as well as the SARS-CoV-2 specific C135 (Barnes et al., 2020b) , also 332 neutralize SARS-CoV-2 without blocking ACE2 binding. As 2H04 neutralizes SARS-CoV-2 by 333 reducing cellular attachment without blocking ACE2 engagement, we predict that S309 and C135 also 334 inhibit SARS-CoV-2 infection through a similar mechanism. Although 2H04 exhibits relatively low 335 affinity binding to SARS-CoV RBD, it may be possible to enhance the affinity of 2H04 for SARS-CoV 336 RBD by structure-guided mutagenesis, thus enhancing cross-neutralization of 2H04, enabling its neutralization, and that mutations at identical residues have been observed in naturally occuring 340 SARS-CoV-2 variants, suggests that SARS-CoV-2 might escape antibody-mediated neutralization 341 when used as monotherapy. In line with these predictions, variants of SARS-CoV-2 containing RBD 342 mutations which disrupt neutralization by RBM-targeting antibodies, including 2B04 and 2H04, and 343 convalescent and vaccinee serum-derived polyclonal antibodies, have recently emerged ( Figure 5) 344 Garcia-Beltran et al., 2021; Wang et al., 2021a Wang et al., , 2021b . K417, E484, and N501 345 are substituted in multiple variants of concern and are contact residues for a variety of previously 

Citations for GISAID sequence data can be found in Table S2 -generated 09/16/2020 468 J o u r n a l P r e -p r o o f

Further information and requests for resources and reagents should be directed to and will be fulfilled  Density maps used to build models were deposited in the EMDB with the following accession 

Untagged RBD was expressed in E. coli BL21(DE3) cells and oxidatively refolded from 511 inclusion bodies as previously described (Oliphant et al., 2007) . RBD variants were made using a Q5

Site-Directed Mutagenesis Kit (NEB), and were expressed and purified as described for WT RBD.

Genes encoding human ACE2 (hACE2 residues 1-615) were synthesized (IDT) and placed into a 

Micrograph contrast transfer function correction parameters were estimated using GCTF v1.06 543 (Zhang, 2016) . Particles were picked on each dataset using CrYOLO v1.7.1 employing a general 544 model (Wagner et al., 2019) . Particles were first subjected to 2D classification in relion 3.1 (Scheres, 545 2012; Zivanov et al., 2018) . Good 2D classes from both holey lacey carbon and thin-film lacey carbon 546 particle sets were picked and merged for both 2B04 and 2H04. The merged particle datasets were 547 then subjected to 3D classification using a 7.5 degree angular search for 25 iterations followed by 25 548 iterations of local searches at 1.8 degree sampling to separate spike conformational states, as 549 J o u r n a l P r e -p r o o f previously described . Particles for each conformational state were put through 550 CTF refinement and Bayesian polishing in relion 3.1 (Zivanov et al., 2019) prior to non-uniform 551 refinement in cryoSPARC v2.15 to generate the final full-spike maps (Punjani et al., 2017) . To 552 enhance resolution and map quality at the Fab/RBD interface, masks encompassing either one F V 553 and RBD of the U/D/D 2B04 dataset or all three F V and RBD positions for the D/D/D 2H04 dataset 554 were used for focused classification on their respective particle sets in relion 3.1. Classes with well-555 resolved detail in the masked region were selected, and the particles expanded with C3 symmetry.

Finally, the particles were subjected to local non-uniform refinement in cryoSPARC v2.15 using a 557 mask encompassing one F V /RBD for both 2B04 and 2H04 to generate the locally refined maps.

Model building

For the locally refined maps, an initial model was generated by using protein BLAST with the Fab 561 sequences to identify pre-existing Fab models that displayed high sequence similarity to 2B04 (PDB: 

PHENIX: a comprehensive Python-based system for macromolecular structure solution

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

ISOLDE : a physically realistic environment for model building into low-resolution electron-density maps

An interactive web-based dashboard to track COVID-19 in real time

Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity

Features and development of Coot

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

UCSF ChimeraX: Meeting modern challenges in visualization and analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

Induction of epitope-specific neutralizing antibodies against West Nile virus

ACE2-independent interaction of SARS-CoV-2 spike protein to human epithelial cells can be inhibited by unfractionated heparin

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

A Bayesian view on cryo-EM structure determination

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

GISAID: Global initiative on sharing all influenza data -from vision to reality

CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A human monoclonal antibody blocking SARS-CoV-2 infection

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structural basis of a shared antibody response to SARS-CoV-2

Gctf: Real-time CTF determination and correction

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

A pneumonia outbreak associated with a new coronavirus of probable bat origin

New tools for automated high-resolution cryo-EM structure determination in RELION-3

A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis

Potently neutralizing and protective human antibodies against SARS-CoV-2